Surgical redo versus transseptal or transapical transcatheter mitral valve-in-valve implantation for failed mitral valve bioprosthesis.

Federico SimonettoPaola A M Purita Massimiliano MalerbaMarco BarbieratoAndrea PascottoDomenico ManginoChiara ZanchettinFrancesco CardaioliGino GerosaAugusto D'OnofrioCarlo CernettiLuca FaveroAlessandro DaniottiGiuseppe MinnitiFrancesco CaprioglioGiovanna ErenteTommaso Hinna DanesiAnna Chiara FrigoFederico Ronco

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)

For the selected patients, TS-TMViV and TA-TMViV are to be considered a valid alternative to redo-SMVR with comparable 1-year survival. TS-TMViV is the less invasive strategy and has the advantage of shortening the LOS compared with TA-TMViV.

Keyphrases

mitral valve
left atrial
aortic valve replacement
left ventricular
end stage renal disease
ejection fraction
aortic valve
aortic stenosis
newly diagnosed
transcatheter aortic valve implantation
prognostic factors
peritoneal dialysis
heart failure